Evidence map›Paper›PMID 35893700›Full record

ReviewViruses2022

Beyond Amyloid Fibers: Accumulation, Biological Relevance, and Regulation of Higher-Order Prion Architectures.

Wesley R Naeimi, Tricia R Serio

Abstract readReview
In one paragraph

Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Multiple aspects of amyloid dynamicsFrontiers in molecular neuroscience · 2024
    Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wesley R NaeimiDepartment of Biochemistry and Molecular Biology, The University of Massachusetts Amherst, Amherst, MA 01003, USA.
Tricia R SerioDepartment of Biochemistry and Molecular Biology, The University of Massachusetts Amherst, Amherst, MA 01003, USA.ORCID 0000-0003-2687-7372

Funding

Cellular Mechanisms and Consequences of Protein Misfolding and ResolutionR35GM118042 · NIGMS · UNIVERSITY OF WASHINGTON · PI SERIO, TRICIA R. · 2016 to 2025
$3.3M
NIGMS NIH HHS R35 GM118042
6 · The paper itself

Abstract

The formation of amyloid fibers is associated with a diverse range of disease and phenotypic states. These amyloid fibers often assemble into multi-protofibril, high-order architectures in vivo and in vitro. Prion propagation in yeast, an amyloid-based process, represents an attractive model to explore the link between these aggregation states and the biological consequences of amyloid dynamics. Here, we integrate the current state of knowledge, highlight opportunities for further insight, and draw parallels to more complex systems in vitro. Evidence suggests that high-order fibril architectures are present ex vivo from disease relevant environments and under permissive conditions in vivo in yeast, including but not limited to those leading to prion formation or instability. The biological significance of these latter amyloid architectures or how they may be regulated is, however, complicated by inconsistent experimental conditions and analytical methods, although the Hsp70 chaperone Ssa1/2 is likely involved. Transition between assembly states could form a mechanistic basis to explain some confounding observations surrounding prion regulation but is limited by a lack of unified methodology to biophysically compare these assembly states. Future exciting experimental entryways may offer opportunities for further insight.

Indexed as

PrionsSaccharomyces cerevisiae ProteinsAmyloidAmyloidogenic ProteinsSaccharomyces cerevisiaeAmyloidAmyloidogenic ProteinsPrionsSaccharomyces cerevisiae Proteinsamyloidamyloidosisfibrilprionprotofibrils[PSI+]

Identifiers

PMID35893700
PMCPMC9332770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.